The DEA Tried to Ban Kratom Once. Users Beat It Back. This Time, It's Betting They're Too Sick to Fight.

Julie Craig has spent enough years in addiction medicine to know what it looks like when a patient is about to lose the thing that’s been keeping them out of a fentanyl supply that would kill them. In a KevinMD essay published September 3, she laid out what’s coming for the people who’ve spent the last two or three years managing opioid withdrawal, chronic pain, or a habit they never told their doctor about with 7-hydroxymitragynine — a concentrated extract sold as shots and tablets at gas stations and vape shops under names like “OPMS Black” and “Zaza.” Withdrawal from it, she wrote, can “come on fast and mimic the effects of stopping heroin and methamphetamines all at once.” And starting this fall, for a lot of people, it’s simply going away.

The DEA is not making 7-OH disappear. It is deciding, again, that the people who depend on it can disappear instead.

That’s the plain version of what a temporary scheduling order — moving through the Drug Enforcement Administration since July — actually does. 7-hydroxymitragynine, or 7-OH, is a compound your body already makes in tiny amounts when it breaks down mitragynine, the main active ingredient in the kratom plant. What’s sold on shelves now isn’t that trace metabolite; it’s a lab-concentrated version of it, engineered to be far stronger than anything a kratom leaf ever produced on its own — potent enough at the same opioid receptors fentanyl binds to that researchers describe it as 30 to 40 times more active than the alkaloids in ordinary kratom tea. Put simply: it’s an opioid, sold next to the energy drinks, and nobody at the register is required to tell you that.

If you have ever bought one of those shots to get through a Tuesday without dope-sick shaking, you already know the parts of this story nobody writing about “kratom policy” usually bothers to mention: the taste, the specific gas station that keeps it in stock, the math you do about how many hours a $12 bottle buys you. This piece is for you as much as it’s for the providers reading it. You are the subject of this policy, not a footnote in it.

What the DEA is actually banning, and what it isn’t

The order moving through DEA this year is narrower than it sounds and broader than the industry wants you to believe. On August 26, the agency placed three synthetic derivatives — mitragynine pseudoindoxyl, MGM-15, and MGM-16 — onto Schedule I, the same legal category as heroin. 7-OH itself hasn’t been scheduled yet — the DEA reopened public comment on a proposed threshold, 0.05% 7-OH content, and left the window open until September 10. Cross that line, under the proposal, and a product becomes a controlled substance overnight. Stay under it — as raw kratom leaf and traditional tea preparations do — and you’re untouched.

That distinction matters enormously and gets flattened in almost every headline about it. The DEA and FDA are not proposing to schedule kratom, the plant Southeast Asian communities have used for centuries and an estimated several million Americans use today, mostly for pain, energy, or mood, mostly without incident. They’re targeting the industrial extraction process that takes a mild plant alkaloid and turns it into something pharmacologically closer to a synthetic opioid — the same drift the Addiction journal documented in a November 2025 paper tracking the rise of these “semi-synthetic” 7-OH products as a category distinct from kratom itself. Christopher McCurdy, the University of Florida medicinal chemist whose lab has spent two decades characterizing kratom’s pharmacology, has made the same point for years: labeling the whole plant an opioid is, in his words, “scientifically and factually incorrect.” The compound the DEA is chasing this time is a different animal than the one it went after in 2016 — but the people caught in the crossfire are the same people, again.

That distinction matters enormously and gets flattened in almost every headline about it.

The government has run this experiment before

We have watched a federal agency decide it can ban its way out of a drug problem before, and watched the users it targeted fight back hard enough to win. On August 30, 2016, the DEA announced its intent to emergency-schedule mitragynine and 7-OH — meaning all of kratom, leaf and all — into Schedule I within 30 days, no public comment period required. What followed was, by DEA’s own admission, unprecedented: more than 140,000 signatures on a White House petition, a bipartisan letter from over 50 members of Congress, kratom vendors suing to block the order, and advocates showing up at the DEA’s own front door in Arlington, Virginia. Six weeks later, on October 12, 2016, the DEA withdrew the notice entirely, an outcome so rare for a scheduling action that NPR called it a genuine reprieve rather than a delay. The agency opened a new public comment period instead and never scheduled the plant.

That backlash worked because the people leading it were, for the most part, functional. They were kratom tea drinkers organizing petitions on their lunch breaks, small-business owners with something to lose, people healthy enough to fly to D.C. This year’s target population looks different. The DEA isn’t threatening the guy who orders loose-leaf kratom powder online to manage his knee. It’s threatening the person who is, by the clinical definition, physically dependent on a fast-acting opioid-receptor agonist they’ve been buying legally at a gas station — someone for whom six weeks without it isn’t an inconvenience, it’s a medical event.

Withdrawal doesn’t organize a letter-writing campaign

Here’s the mechanism, translated out of the pharmacology journals: your brain’s opioid receptors adapt to a steady supply of anything that activates them hard enough, often enough. Cut the supply and the receptors that adapted don’t switch back overnight — you get a rebound of exactly the symptoms the drug had been suppressing, amplified. That’s withdrawal. It’s not weakness and it’s not in your head; it’s your nervous system correcting for a chemical presence it had learned to expect. For 7-OH specifically, because it’s fast-acting and short-lived in the body, that rebound can hit within hours and peak within a day or two — which is part of why Craig describes it as mimicking full-blown opioid withdrawal rather than the milder discomfort some kratom leaf users report.

That is not a population that mobilizes the way the 2016 tea-drinking crowd did. It’s a population that, per Craig’s essay, is more likely to do what people in withdrawal have always done when the thing holding them together disappears: find the next thing that will. “Dependent users suddenly losing access,” she wrote, “may go to any source of relief, including far more dangerous but widely available opioids like fentanyl” — a substitution risk made worse by the fact that most 7-OH users have no fentanyl tolerance at all, which is exactly the setup for the overdoses that follow prohibition, not the ones it prevents. Craig’s argument for why bans keep failing to shrink the supply of anything: “prohibition has never meant fewer drugs are available,” she wrote, pointing to the 117 years since the U.S. first banned opium and still hasn’t run out of opioids.

On kratom-recovery forums this summer, that dynamic was already visible before DEA published a word of the final rule — a community signal worth naming, not quoting: people posting timelines for stockpiling 7-OH shots before their local shops pulled them, and others posting the withdrawal clock in real time — the sweating and gut cramps at hour six, the crawling skin by hour twelve, and by day three, several said, they’d already switched to something else because nothing else was in reach. None of that is a controlled study. It’s the same pattern Craig is describing from the exam room, showing up from the other direction.

It’s the same pattern Craig is describing from the exam room, showing up from the other direction.

If you’re a case manager or a peer navigator reading this with a client who’s been using kratom or 7-OH to stay off something worse, this is not a policy footnote for your files — it’s a conversation to have this week, before the shelf empties on its own. Ask plainly what they’re using, how much, and what their plan is if it’s gone by Halloween. That conversation, had now, is cheaper than the one you’ll have in an ER waiting room in November.

The regulation nobody in Washington is funding

There is a version of this policy that threads the needle Craig and researchers like McCurdy have both pointed toward: regulate 7-OH the way responsible states regulate cannabis, not the way the DEA regulates heroin. Potency caps. Mandatory lab testing so a $12 bottle can’t secretly contain three times the 7-OH of the one next to it. Age verification. Point-of-sale labeling that actually says “this is an opioid” in words a teenager in a gas station can read. None of that requires Schedule I. All of it requires an agency willing to build regulatory infrastructure instead of a prohibition list — and Washington has shown, repeatedly, that the list is cheaper to produce than the infrastructure, even when the list doesn’t work.

We’ve watched this exact substitution effect play out with a different drug in real time this year: after Pennsylvania scheduled xylazine as a fentanyl-supply adulterant in 2024, a quasi-experimental study posted to medRxiv in May found xylazine didn’t meaningfully decline in the drug supply — medetomidine, an unscheduled and even more potent alpha-2 agonist, simply moved in to fill the gap. Ban one molecule and, if the demand underneath it doesn’t move, the supply chain finds the next molecule with a similar effect and a blank legal slate. There is no reason to expect kratom’s synthetic derivatives to behave differently, and every reason — Craig’s, McCurdy’s, and now a mounting body of adulterant-substitution research — to expect them to.

Naloxone is still free at most syringe service programs and most Arizona pharmacies without a prescription, whatever happens to 7-OH on a shelf next month — that fact doesn’t get less true because a scheduling order is moving through the Federal Register. Neither does the number for the SAMHSA National Helpline, 1-800-662-4357, which stays open regardless of what Congress does to any single line item. Hold onto both. The DEA has, once before, looked at exactly this fight and backed down — not because it changed its mind about the risk, but because the people affected made themselves impossible to ignore. This time, the people most affected are the ones least able to show up at the DEA’s front door. That doesn’t mean the risk they’re carrying is smaller. It means the burden of showing up for them just moved to everyone else who can.